Alefacept is well tolerated in patients with chronic plaque psoriasis

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Traditional systemic treatments for moderate to severe chronic plaque psoriasis are often poorly tolerated and are associated with safety concerns that restrict their long-term use. Alefacept is a fully human fusion protein that selectively targets memory T cells, and it is expected to provide enhanced safety over traditional nonselective agents. The safety and tolerability profile of alefacept is reviewed using data from the clinical development program. The most common adverse events were similar among alefacept and placebo groups. As expected from its mechanism of action, alefacept reduced the number of CD4 + and CD8+ T cells, with selectivity for the memory subsets. This reduction was not associated with an increase in the incidence of infections. Alefacept was not immunogenic. Patients have received up to six courses of alefacept therapy and the safety and tolerability profile over multiple courses is similar to that of a single course. Alefacept offers hope for a safer means to provide long-term management of psoriasis.

Original languageEnglish
Pages (from-to)14-19
Number of pages6
JournalJournal of Cutaneous Medicine and Surgery
Volume8
Issue numberSUPPL. 2
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Dive into the research topics of 'Alefacept is well tolerated in patients with chronic plaque psoriasis'. Together they form a unique fingerprint.

Cite this